|Videos|December 29, 2022

Importance of Screening for T1D

Author(s)Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, Kimberly Simmons, MD

Tina Q Tan, MD, and Kimberly Simmons, MD, comment on early screening for pediatric T1D, screening options, and next steps once a child has tested positive for 2 or more autoantibodies.

Episodes in this series

EP. 1 Prevalence and Risk Factors of Pediatric Type 1 Diabetes (T1D)

EP. 1 Prevalence and Risk Factors of Pediatric Type 1 Diabetes (T1D)

EP. 2 Stages and Progression of T1D

EP. 2 Stages and Progression of T1D

EP. 3 Importance of Screening for T1D

EP. 3 Importance of Screening for T1D

EP. 4 Lifestyle Management in T1D

EP. 4 Lifestyle Management in T1D

EP. 5 Approaching T1D Screening Retesting

EP. 5 Approaching T1D Screening Retesting

EP. 6 Emerging Treatments in T1D

EP. 6 Emerging Treatments in T1D

EP. 7 Blood Glucose Monitoring in T1D

EP. 7 Blood Glucose Monitoring in T1D

EP. 8 Key Takeaways for Screening and Diagnosis of T1D

EP. 8 Key Takeaways for Screening and Diagnosis of T1D

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Related Content

FDA authorizes first dual glucose-ketone monitor for children as young as 2

FDA authorizes first dual glucose-ketone monitor for children as young as 2

ByMorgan Ebert, Executive Editor

August 25th 2026

Family history alone may not prompt type 1 diabetes screening, survey finds | Image Credit: © Africa Studio - stock.adobe.com

Family history alone may not prompt type 1 diabetes screening, survey finds

ByMorgan Ebert, Executive Editor

July 30th 2026

Tzield approved to preserve insulin production in children with newly diagnosed type 1 diabetes

Tzield approved to preserve insulin production in children with newly diagnosed type 1 diabetes

ByMorgan Ebert, Executive Editor

June 15th 2026

ADA 2026 data highlight pediatric outcomes and treatment satisfaction with Afrezza

ADA 2026 data highlight pediatric outcomes and treatment satisfaction with Afrezza

ByMorgan Ebert, Executive Editor,Kevin Kaiserman, MD

June 11th 2026

Jamie Wood, MD, on the significance of the Afrezza approval for pediatric diabetes

Jamie Wood, MD, on the significance of the Afrezza approval for pediatric diabetes

ByJamie Wood, MD

June 4th 2026

Latest CME

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Jordan Axelrad, MD, MPH, FACG, FCCF; Jessica R. Allegretti, MD, MPH; Florian Rieder, MD

Trending on Contemporary Pediatrics

Abbott launches first ready-to-feed whole milk infant formula in the U.S.

Semaglutide improves BMI category in children aged 6 to 11 years in phase 3 trial

ARTEMIS trial data show Bifidobacterium-HMO synbiotic is safe and colonizes the infant, toddler gut

Can you guess the diagnosis of this teenaged girl with flat-topped papules?

FDA news in pediatrics: August 2026